Moneycontrol Be a Pro
Get App
you are here: HomeNewsBusiness
Last Updated : Mar 07, 2019 07:48 PM IST | Source: PTI

Lupin gets USFDA nod to market its cholesterol lowering drug

The product is a generic version of Pfizer Inc's Lipitor tablets in the same strengths.

  • bselive
  • nselive
Todays L/H

Drug firm Lupin on Thursday said it has received nod from the US health regulator to market its generic Atorvastatin Calcium tablets, used for lowering cholesterol, in the American market.

The company has received approval from the United States Food and Drug Administration (USFDA) to market its Atorvastatin Calcium tablets in the strengths of 10 mg, 20 mg, 40 mg, and 80 mg, Lupin said in a filing to the BSE.

The product is a generic version of Pfizer Inc's Lipitor tablets in the same strengths, it added.


The tablets are indicated to lower cholesterol in blood for adults and children over 10 years of age, Lupin said.

Atorvastatin is also prescribed to lower the risk for heart attack, stroke in patients with cardiovascular diseases, diabetes and other risk factors such as eye problems, kidney diseases or high blood pressure, it added.

According to IQVIA MAT December 2018 data, Atorvastatin Calcium tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg had annual sales of around USD 696 million in the US, it said.

Shares of Lupin Ltd closed at Rs 791.10 per scrip on the BSE, up 0.31 per cent from its previous close.

The Great Diwali Discount!
Unlock 75% more savings this festive season. Get Moneycontrol Pro for a year for Rs 289 only.
Coupon code: DIWALI. Offer valid till 10th November, 2019 .
First Published on Mar 7, 2019 07:42 pm
Follow us on
Available On
PCI DSS Compliant